Klaus Christian Schollmeier
Président chez Embark Laboratories ApS
Profil
Klaus Christian Schollmeier is currently the Chairman at Embark Laboratories ApS.
He was previously the Chairman at Novo Nordisk Research Center Gladsaxe ApS.
Postes actifs de Klaus Christian Schollmeier
| Sociétés | Poste | Début |
|---|---|---|
Embark Laboratories ApS
 Embark Laboratories ApS BiotechnologyHealth Technology Embark Laboratories ApS is a Danish biotech company that focuses on cardiometabolic disease. The private company is based in Copenhagen, Denmark. The company was founded in 2023. Casper Tind Hansen has been the CEO of the company since 2023. | Président | 05/07/2023 |
Anciens postes connus de Klaus Christian Schollmeier
| Sociétés | Poste | Fin |
|---|---|---|
Embark Biotech ApS
 Embark Biotech ApS Miscellaneous Commercial ServicesCommercial Services Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million. | Président | 29/08/2023 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Embark Biotech ApS
Embark Biotech ApS Miscellaneous Commercial ServicesCommercial Services Novo Nordisk Research Center Gladsaxe ApS is based in Bagsværd, Denmark. The Danish company is a spin-out from the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) at the University of Copenhagen. The company discovered a novel target that suppresses appetite, increases energy expenditure, and enhances insulin sensitivity. The development of the target was initiated through a collaboration with Novo Nordisk and further matured with support from the Innobooster program at the Innovation Fund Denmark and the Bioinnovation Institute (BII) during a residency in the Venture House program. Part of Novo Nordisk A/S, Novo Nordisk Research Center Gladsaxe ApS is a biotech company that was founded in 2017. The CEO of the company is Casper Tind Hansen. Novo Nordisk Research Center Gladsaxe was acquired by Novo Nordisk A/S from Embark Laboratories ApS on August 28, 2023 for $68.06 million. | Commercial Services |
Embark Laboratories ApS
Embark Laboratories ApS BiotechnologyHealth Technology Embark Laboratories ApS is a Danish biotech company that focuses on cardiometabolic disease. The private company is based in Copenhagen, Denmark. The company was founded in 2023. Casper Tind Hansen has been the CEO of the company since 2023. | Health Technology |
